Overview

Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W

Status:
NOT_YET_RECRUITING

Trial end date:
2028-08-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy and safety of adding the immunotherapy Avelumab as a fourth component, alongside tumor removal, chemotherapy, and radiation, to increase the chance of preserving the bladder in the treatment of muscle-invasive bladder cancer.

Phase:

PHASE2

Details

Lead Sponsor:

American University of Beirut Medical Center

Collaborator:

Merck KGaA, Darmstadt, Germany

Treatments:

Drug Therapy
Palliative Care
Radiotherapy
Watchful Waiting